IL202648B - Aqueous pharmaceutical preparations containing vla-4 binding antibodies for the treatment of inflammatory, immune and autoimmune diseases - Google Patents
Aqueous pharmaceutical preparations containing vla-4 binding antibodies for the treatment of inflammatory, immune and autoimmune diseasesInfo
- Publication number
- IL202648B IL202648B IL202648A IL20264809A IL202648B IL 202648 B IL202648 B IL 202648B IL 202648 A IL202648 A IL 202648A IL 20264809 A IL20264809 A IL 20264809A IL 202648 B IL202648 B IL 202648B
- Authority
- IL
- Israel
- Prior art keywords
- vla
- immune
- inflammatory
- treatment
- pharmaceutical compositions
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 208000026278 immune system disease Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94407607P | 2007-06-14 | 2007-06-14 | |
| PCT/US2008/066928 WO2008157356A2 (en) | 2007-06-14 | 2008-06-13 | Antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL202648A0 IL202648A0 (en) | 2011-08-01 |
| IL202648B true IL202648B (en) | 2018-04-30 |
Family
ID=39956053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL202648A IL202648B (en) | 2007-06-14 | 2009-12-10 | Aqueous pharmaceutical preparations containing vla-4 binding antibodies for the treatment of inflammatory, immune and autoimmune diseases |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20080311119A1 (enExample) |
| EP (2) | EP2170390B1 (enExample) |
| JP (2) | JP2010529999A (enExample) |
| CN (2) | CN103977404A (enExample) |
| AR (2) | AR067011A1 (enExample) |
| AU (1) | AU2008266051B2 (enExample) |
| BR (1) | BRPI0814252B8 (enExample) |
| CA (1) | CA2690382A1 (enExample) |
| CY (1) | CY1121208T1 (enExample) |
| DK (1) | DK2170390T3 (enExample) |
| EA (1) | EA020456B1 (enExample) |
| ES (1) | ES2707815T3 (enExample) |
| HR (1) | HRP20182146T1 (enExample) |
| HU (1) | HUE041555T2 (enExample) |
| IL (1) | IL202648B (enExample) |
| LT (1) | LT2170390T (enExample) |
| MX (2) | MX2009013593A (enExample) |
| NZ (2) | NZ595526A (enExample) |
| PL (1) | PL2170390T3 (enExample) |
| PT (1) | PT2170390T (enExample) |
| SI (1) | SI2170390T1 (enExample) |
| TR (1) | TR201820837T4 (enExample) |
| TW (1) | TWI614028B (enExample) |
| WO (1) | WO2008157356A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3777880A1 (en) | 2003-02-10 | 2021-02-17 | Biogen MA Inc. | Immunoglobulin formulation and method of preparation thereof |
| EP2453874A2 (en) * | 2009-07-14 | 2012-05-23 | Biogen Idec MA Inc. | Methods for inhibiting yellow color and peroxide formation in a composition |
| CA2789061A1 (en) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
| LT3345615T (lt) | 2010-03-01 | 2020-02-10 | Bayer Healthcare Llc | Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi) |
| PT3202789T (pt) | 2010-04-16 | 2020-06-16 | Biogen Ma Inc | Anticorpos anti-vla-4 |
| RS66182B1 (sr) | 2010-05-28 | 2024-12-31 | Novo Nordisk As | Stabilne višedozne kompozicije koje sadrže antitelo i konzervans |
| WO2013006461A1 (en) * | 2011-07-01 | 2013-01-10 | Biogen Idec Ma Inc. | Cholesterol-based media supplementals for cell culture |
| US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
| AR088381A1 (es) | 2011-10-18 | 2014-05-28 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con meglumina |
| WO2013123114A2 (en) * | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| CN104520326A (zh) * | 2012-06-21 | 2015-04-15 | Ucb医药有限公司 | 药物制剂 |
| IN2015KN00005A (enExample) | 2012-07-09 | 2015-07-31 | Coherus Biosciences Inc | |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| MX360044B (es) | 2012-09-11 | 2018-10-19 | Coherus Biosciences Inc | Etanercept plegado correctamente con alta pureza y un rendimiento excelente. |
| CN103217525B (zh) * | 2013-03-21 | 2015-04-29 | 上海执诚生物科技股份有限公司 | 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途 |
| WO2015063180A1 (en) * | 2013-10-29 | 2015-05-07 | Novozymes Biopharma Dk A/S | Antibody composition |
| KR102362002B1 (ko) * | 2013-11-29 | 2022-02-10 | 제넨테크, 인크. | 항체 선택 장치 및 방법 |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| JP2017510627A (ja) * | 2014-03-13 | 2017-04-13 | プロセナ バイオサイエンシーズ リミテッド | 多発性硬化症の併用治療 |
| BR112016028182A2 (pt) * | 2014-06-02 | 2018-02-20 | Lab Francais Du Fractionnement | método para produzir um fragmento de fragmento cristalizável, e, fragmento fc. |
| MX2017004975A (es) * | 2014-10-18 | 2017-06-30 | Pfizer | Composiciones de anticuerpos anti-il-7r. |
| MX2018014560A (es) | 2016-05-27 | 2019-08-12 | Alexion Pharma Inc | Metodos para el tratamiento de la miastenia gravis generalizada refractaria. |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| GB201703062D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| CA3080187A1 (en) | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| CN112292146A (zh) * | 2018-04-10 | 2021-01-29 | 雷迪博士实验室有限公司 | 治疗性抗体的稳定的制剂 |
| WO2019236417A1 (en) | 2018-06-04 | 2019-12-12 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| WO2021007504A2 (en) * | 2019-07-10 | 2021-01-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising reduced level of host cell proteins |
| EP4021497A4 (en) * | 2019-08-30 | 2023-09-06 | Kashiv Biosciences, LLC | NOVEL FORMULATION OF A HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODIES |
| CN113134081A (zh) * | 2020-01-20 | 2021-07-20 | 上海君实生物医药科技股份有限公司 | 抗btla抗体药物组合物及其用途 |
| JPWO2022092183A1 (enExample) * | 2020-10-30 | 2022-05-05 | ||
| KR20230107644A (ko) | 2020-11-14 | 2023-07-17 | 바이오젠 엠에이 인코포레이티드 | 항-vla-4 항체에 대한 2상 피하 투여 요법 |
| EP4323407A1 (en) | 2021-04-13 | 2024-02-21 | Biogen MA Inc. | Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4475196A (en) * | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| JPS62196921A (ja) | 1986-02-25 | 1987-08-31 | Nec Corp | 位相検出回路 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5383851A (en) * | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| RU2185393C2 (ru) | 1993-01-06 | 2002-07-20 | Кинертон Лимитед | Сложный полиэфир и конъюгат на его основе |
| NZ261259A (en) | 1993-01-12 | 1996-12-20 | Biogen Inc | Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments |
| AU687790B2 (en) * | 1993-02-09 | 1998-03-05 | Biogen Idec Ma Inc. | Treatment for insulin dependent diabetes |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| DK0804237T3 (da) * | 1994-01-25 | 2006-10-16 | Elan Pharm Inc | Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4 |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| CN103275221B (zh) | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| WO2001055112A1 (en) | 2000-01-27 | 2001-08-02 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| EP3777880A1 (en) * | 2003-02-10 | 2021-02-17 | Biogen MA Inc. | Immunoglobulin formulation and method of preparation thereof |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| EP1827491A4 (en) * | 2004-11-19 | 2010-07-14 | Biogen Idec Inc | TREATMENT OF MULTIPLE SCLEROSIS |
| WO2008021954A2 (en) | 2006-08-09 | 2008-02-21 | Biogen Idec Ma Inc. | Method for distribution of a drug |
-
2008
- 2008-06-13 HR HRP20182146TT patent/HRP20182146T1/hr unknown
- 2008-06-13 TR TR2018/20837T patent/TR201820837T4/tr unknown
- 2008-06-13 PT PT08771026T patent/PT2170390T/pt unknown
- 2008-06-13 CN CN201410163087.4A patent/CN103977404A/zh active Pending
- 2008-06-13 DK DK08771026.5T patent/DK2170390T3/en active
- 2008-06-13 SI SI200832029T patent/SI2170390T1/sl unknown
- 2008-06-13 MX MX2009013593A patent/MX2009013593A/es active IP Right Grant
- 2008-06-13 TW TW097122335A patent/TWI614028B/zh active
- 2008-06-13 EA EA201070015A patent/EA020456B1/ru unknown
- 2008-06-13 US US12/139,362 patent/US20080311119A1/en not_active Abandoned
- 2008-06-13 AU AU2008266051A patent/AU2008266051B2/en active Active
- 2008-06-13 NZ NZ595526A patent/NZ595526A/xx unknown
- 2008-06-13 AR ARP080102545A patent/AR067011A1/es not_active Application Discontinuation
- 2008-06-13 EP EP08771026.5A patent/EP2170390B1/en active Active
- 2008-06-13 BR BRPI0814252A patent/BRPI0814252B8/pt active IP Right Grant
- 2008-06-13 LT LTEP08771026.5T patent/LT2170390T/lt unknown
- 2008-06-13 PL PL08771026T patent/PL2170390T3/pl unknown
- 2008-06-13 ES ES08771026T patent/ES2707815T3/es active Active
- 2008-06-13 HU HUE08771026A patent/HUE041555T2/hu unknown
- 2008-06-13 NZ NZ582436A patent/NZ582436A/en unknown
- 2008-06-13 JP JP2010512385A patent/JP2010529999A/ja active Pending
- 2008-06-13 EP EP18193307.8A patent/EP3461500A1/en active Pending
- 2008-06-13 CN CN200880102434A patent/CN101778640A/zh active Pending
- 2008-06-13 WO PCT/US2008/066928 patent/WO2008157356A2/en not_active Ceased
- 2008-06-13 CA CA2690382A patent/CA2690382A1/en not_active Abandoned
-
2009
- 2009-12-10 IL IL202648A patent/IL202648B/en active IP Right Grant
- 2009-12-11 MX MX2020005214A patent/MX2020005214A/es unknown
-
2012
- 2012-01-27 US US13/359,959 patent/US20120134989A1/en not_active Abandoned
- 2012-06-22 US US13/530,879 patent/US9533044B2/en active Active
-
2013
- 2013-09-04 JP JP2013182749A patent/JP2014040424A/ja active Pending
-
2019
- 2019-02-01 CY CY20191100146T patent/CY1121208T1/el unknown
- 2019-03-19 AR ARP190100691A patent/AR117403A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL202648B (en) | Aqueous pharmaceutical preparations containing vla-4 binding antibodies for the treatment of inflammatory, immune and autoimmune diseases | |
| IL272817A (en) | New preparations and methods for the treatment of vaccine-related diseases | |
| IL215123A0 (en) | Polymer-agent conjugates, particles, compositions, and related methods of use | |
| IL215773A (en) | Acetidinyl Diamides, Pharmaceuticals containing them and their uses | |
| IL204886B (en) | A pharmaceutical preparation for the treatment of disorders of the stomach and intestines independent of food consumption | |
| IL203142A (en) | Anti-B antibody CD79, pharmaceuticals including them, their use and method of preparation | |
| IL204536A (en) | 6il anti-receptor antibodies and medical preparations containing them | |
| IL238395B (en) | Soluble attachment components of human serum, preparations and methods for their production | |
| SG10201510665WA (en) | Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders | |
| WO2011049960A9 (en) | Compositions and methods for the treatment of sinonasal disorders | |
| EP2285347A4 (en) | COMPOSITIONS AND METHODS OF TREATING DISORDERS OF THE DIGESTION SYSTEM | |
| IL212545A (en) | Isolated antibodies that bind to 3tlr and their pharmaceutical preparations | |
| ZA200906388B (en) | Compositions and methods for enhancing immune system of felines | |
| EP2447253A4 (en) | DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| IL217839A (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| IL208782A0 (en) | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders | |
| EP1996218A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | |
| PL2504331T3 (pl) | Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie | |
| ZA201200079B (en) | Pharmaceutical compositions and solid forms | |
| IL211904A (en) | Kit and preparations containing methotrexate and anti-cd4 antibody for the treatment of rheumatic disease | |
| HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
| IL219050B (en) | A pharmaceutical preparation for the treatment of bladder disorders | |
| SI2344166T1 (sl) | Farmacevtska sestava za zdravljenje gastrointestinalnih iritacij | |
| EP2394649A4 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL-CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | |
| WO2011080050A3 (en) | Ccl21 binding molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |